Vanguard Investments Australia
TRAX

Vanguard Investments Australia’s First Tracks Biotherapeutics TRAX Stock Holding History

Vanguard Investments Australia’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Buy
+6,350
New +$119K ﹤0.01% 2265

Other funds holding TRAX

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Investments Australia's TRAX Position: Q2 2026 in Review

Vanguard Investments Australia opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 6,350 shares worth $128K. The stake represents ﹤0.01% of the portfolio and ranks #2265 among its holdings.

136 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Vanguard Investments Australia held 6,350 shares of First Tracks Biotherapeutics worth $128K as of Q2 2026.
  • First Tracks Biotherapeutics was a new Vanguard Investments Australia position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #2265 holding.
  • 136 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.